REGENXBIO NAVSUNLI FDA Aligns on Accelerated Path
REGENXBIO NAVSUNLI FDA said existing data can support accelerated approval and plans BLA resubmission, news that could shift approval bets and positioning.
KEY TAKEAWAYS
- FDA agreed existing NAVSUNLI clinical data can support accelerated approval without new patients or studies.
- REGENXBIO expects a Type A meeting in July 2026 and plans a BLA resubmission in Q3 2026.
- The FDA said it would review the resubmission on an expedited basis and begin labeling discussions.
HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX
Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.
REGENXBIO Inc. (Nasdaq: RGNX) said in a press release on June 22, 2026, that the FDA will consider existing clinical data for accelerated approval of NAVSUNLI (RGX-121), a gene therapy for mucopolysaccharidosis II (MPS II). The agency indicated no additional patients or new studies are needed, prompting a Type A meeting in July and a planned biologics license application (BLA) resubmission in the third quarter.
FDA Alignment and Regulatory Timeline
REGENXBIO described the June exchange with the FDA as part of an appeal following a February complete response letter. The company said regulators confirmed that the existing clinical dataset is sufficient for accelerated approval consideration and that the previously recommended untreated-control arm is no longer required. This change removes a procedural hurdle that had shaped earlier agency feedback.
The FDA also stated it would review the resubmission on an expedited basis and begin labeling discussions shortly after filing. This positions the company for a compressed review process without the need for new patient enrollment or additional trials.
By eliminating the need for new subjects or a control arm, the regulatory path now relies on the current clinical data and the outlined procedural steps rather than further studies. REGENXBIO expects the Type A meeting in July 2026 and plans to resubmit the NAVSUNLI BLA in the third quarter.
Clinical Profile and Commercial Strategy
NAVSUNLI (RGX-121, clemidsogene lanparvovec-sngl) is a one-time investigational gene therapy designed to deliver the iduronate-2-sulfatase (IDS) gene to the central nervous system to treat MPS II, also known as Hunter syndrome. The company presents it as the only potential one-time gene therapy for this rare disease, emphasizing its single-administration clinical profile to support accelerated review.
The therapy holds multiple regulatory designations: Orphan Drug, Rare Pediatric Disease, Fast Track, and Regenerative Medicine Advanced Therapy (RMAT) from the FDA, along with Advanced Therapy Medicinal Product (ATMP) classification from the European Medicines Agency. REGENXBIO said these statuses, combined with its procedural plans, form the basis of its regulatory strategy.
Commercially, the company reiterated its January 2025 partnership with NS Pharma, which would assume U.S. commercialization rights if NAVSUNLI gains approval. REGENXBIO also noted that approval could generate a Priority Review Voucher, offering a potential commercial and development incentive.
The upcoming regulatory steps— the Type A meeting and rapid BLA resubmission—will determine whether the FDA advances the program to post-filing labeling discussions and eventual approval, enabling U.S. commercialization under the existing partnership.
